Free Trial
NASDAQ:NBTX

Nanobiotix (NBTX) Stock Price, News & Analysis

Nanobiotix logo
$2.94 -0.04 (-1.34%)
(As of 01:48 PM ET)

About Nanobiotix Stock (NASDAQ:NBTX)

Key Stats

Today's Range
$2.89
$3.30
50-Day Range
$2.81
$4.96
52-Week Range
$2.76
$8.96
Volume
27,438 shs
Average Volume
21,250 shs
Market Capitalization
$138.57 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$12.00
Consensus Rating
Buy

Company Overview

Nanobiotix S.A., a clinical-stage biotechnology, focuses on developing product candidates for the treatment of cancer and other unmet medical needs. Its lead product candidate is NBTXR3, a sterile aqueous suspension of crystalline hafnium oxide nanoparticles used for the treatment of soft tissue sarcoma, head and neck cancers, liver cancers, prostate cancer, pancreatic cancer, esophageal cancer, rectal cancer, and non-small cell lung cancer. The company has a partnership with Lian Oncology Limited to develop and commercialize NBTXR3 in Greater China, South Korea, Singapore, and Thailand. Nanobiotix S.A. was incorporated in 2003 and is headquartered in Paris, France.

Nanobiotix Stock Analysis - MarketRank™

See Top Rated MarketRank™ Stocks
43rd Percentile Overall Score

NBTX MarketRank™: 

Nanobiotix scored higher than 43% of companies evaluated by MarketBeat, and ranked 657th out of 945 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

  • Consensus Rating

    Nanobiotix has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 2 buy ratings, no hold ratings, and no sell ratings.

  • Amount of Analyst Coverage

    Nanobiotix has received no research coverage in the past 90 days.

  • Read more about Nanobiotix's stock forecast and price target.
  • Earnings Growth

    Earnings for Nanobiotix are expected to grow in the coming year, from ($1.18) to ($0.86) per share.

  • Percentage of Shares Shorted

    0.07% of the outstanding shares of Nanobiotix have been sold short.
  • Short Interest Ratio / Days to Cover

    Nanobiotix has a short interest ratio ("days to cover") of 1.6, which is generally considered an acceptable ratio of short interest to trading volume.
  • Change versus previous month

    Short interest in Nanobiotix has recently increased by 2.32%, indicating that investor sentiment is decreasing.
  • Dividend Yield

    Nanobiotix does not currently pay a dividend.

  • Dividend Growth

    Nanobiotix does not have a long track record of dividend growth.

  • Percentage of Shares Shorted

    0.07% of the outstanding shares of Nanobiotix have been sold short.
  • Short Interest Ratio / Days to Cover

    Nanobiotix has a short interest ratio ("days to cover") of 1.6, which is generally considered an acceptable ratio of short interest to trading volume.
  • Change versus previous month

    Short interest in Nanobiotix has recently increased by 2.32%, indicating that investor sentiment is decreasing.
  • News Sentiment

    Nanobiotix has a news sentiment score of 0.22. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.55 average news sentiment score of Medical companies.
  • News Coverage This Week

    MarketBeat has tracked 2 news articles for Nanobiotix this week, compared to 1 article on an average week.
  • Search Interest

    1 people have searched for NBTX on MarketBeat in the last 30 days.
  • Insider Buying vs. Insider Selling

    In the past three months, Nanobiotix insiders have not sold or bought any company stock.

  • Percentage Held by Insiders

    Only 3.45% of the stock of Nanobiotix is held by insiders.

  • Percentage Held by Institutions

    Only 38.81% of the stock of Nanobiotix is held by institutions.

  • Read more about Nanobiotix's insider trading history.
Receive NBTX Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Nanobiotix and its competitors with MarketBeat's FREE daily newsletter.

NBTX Stock News Headlines

Nanobiotix to Unveil Future of Nanotherapeutics
Could This Tiny Device Help You Make an Extra $30k a Year?
I believe it’s going to power Elon Musk’s next AI revolution… A revolution he believes will be worth more than $9 trillion. That’s nearly 10 times more money than the market caps of Tesla… SpaceX… PayPal… Neuralink… and X… COMBINED.
Nanobiotix’s Market Influence and Innovation Unveiled
Nanobiotix Strengthens Growth and Financial Prospects
See More Headlines

NBTX Stock Analysis - Frequently Asked Questions

Nanobiotix's stock was trading at $7.28 at the beginning of the year. Since then, NBTX shares have decreased by 59.6% and is now trading at $2.94.
View the best growth stocks for 2024 here
.

Nanobiotix (NBTX) raised $95 million in an IPO on Friday, December 11th 2020. The company issued 6,500,000 shares at $14.69 per share. Jefferies, Evercore ISI, UBS Investment Bank and Gilbert DuPont acted as the underwriters for the IPO.

Shares of NBTX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

Based on aggregate information from My MarketBeat watchlists, some other companies that Nanobiotix investors own include PayPal (PYPL), Sirius XM (SIRI), Ardelyx (ARDX), BridgeBio Pharma (BBIO), Cogent Communications (CCOI), Citius Pharmaceuticals (CTXR) and Datadog (DDOG).

Company Calendar

Today
12/24/2024
Fiscal Year End
12/31/2024

Industry, Sector and Symbol

Sector
Medical
Industry
Pharmaceutical preparations
Sub-Industry
Pharmaceutical Products
Current Symbol
NASDAQ:NBTX
Fax
N/A
Employees
100
Year Founded
N/A

Price Target and Rating

Average Stock Price Target
$12.00
High Stock Price Target
$12.00
Low Stock Price Target
$12.00
Potential Upside/Downside
+308.2%
Consensus Rating
Buy
Rating Score (0-4)
3.00
Research Coverage
2 Analysts

Profitability

Pretax Margin
N/A

Debt

Sales & Book Value

Annual Sales
$36.22 million
Book Value
($0.04) per share

Miscellaneous

Free Float
45,507,000
Market Cap
$138.57 million
Optionable
Not Optionable
Beta
0.22
(Almost)  Everything You Need To Know About The EV Market Cover

Click the link below and we'll send you MarketBeat's guide to investing in electric vehicle technologies (EV) and which EV stocks show the most promise.

Get This Free Report

This page (NASDAQ:NBTX) was last updated on 12/24/2024 by MarketBeat.com Staff
From Our Partners